Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Bouin

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 29, 2010
Factors determining utility measured with the EQ-5D in patients with atrial fibrillationJenny Berg, Peter Lindgren, Robby Nieuwlaat, et al.
Nature|July 1, 2016
Policy: Social-progress panel seeks public commentMarc Fleurbaey, Olivier Bouin, Marie-Laure Djelic, et al.
Journal of the American College of Cardiology|September 6, 2005
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialSean C Beinart, Paul Kolm, Emir Veledar, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 29, 2010
Factors determining utility measured with the EQ-5D in patients with atrial fibrillationJenny Berg, Peter Lindgren, Robby Nieuwlaat, et al.
Nature|July 1, 2016
Policy: Social-progress panel seeks public commentMarc Fleurbaey, Olivier Bouin, Marie-Laure Djelic, et al.
Journal of the American College of Cardiology|September 6, 2005
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialSean C Beinart, Paul Kolm, Emir Veledar, et al.
Pageof 1